Lapatinib (GW572016) for advanced or metastatic breast cancer - horizon scanning review
NHSC
Record ID 32005001218
English
Authors' objectives:
This study aims to assess the potential for future impact of Lapatinib (GW572016) for advanced or metastatic breast cancer
Authors' recommendations:
Lapatinib (GW572016) is an oral dual tyrosine kinase inhibitor that is in phase III clinical trials as an additive treatment for women with i) advanced or metastatic hormone-insensitive breast cancer over-expressing HER2 following failure of taxanes, anthracycline and trastuzumab containing regimes in combination with capecitabine, and ii) first-line treatment of hormone-sensitive breast cancer in combination with letrozole in post menopausal women. There are currently no published trials of clinical effectiveness. Phase III trials are ongoing with full patient accrual expected in November 2005 and September 2006.
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2005
URL for published report:
http://www.hsric.nihr.ac.uk/search
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Neoplasm Metastasis
- Quinazolines
- Breast Neoplasms
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.